Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALLK Allakos	$0.33	$0.33	$0.22 ▼ $1.56	$29.74M	0.15	1.23 million shs	N/A
COEP Coeptis Therapeutics	$9.77 -0.7%	$8.83	$2.31 ▼ $13.70	$34.29M	-0.63	120,134 shs	28,798 shs
SXTC China SXT Pharmaceuticals	$1.67 -0.2%	$1.72	$0.95 ▼ $10.24	$193.19M	1.18	1.18 million shs	36,966 shs
YMTX Yumanity Therapeutics		$0.68	$0.95 ▼ $3.78	$7.46M	0.32	473,083 shs	6,790 shs

10 Stocks Set to Soar in Summer 2025

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALLK Allakos	0.00%	0.00%	0.00%	+1.89%	-61.87%
COEP Coeptis Therapeutics	-0.61%	+18.84%	+17.70%	+6.15%	+62.38%
SXTC China SXT Pharmaceuticals	+0.48%	-5.76%	-8.85%	+68.67%	-82.33%
YMTX Yumanity Therapeutics	0.00%	0.00%	0.00%	0.00%	-4.60%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALLK Allakos	3.3239 of 5 stars	3.1	0.0	0.0	4.7	0.0	2.5	1.3
COEP Coeptis Therapeutics	0.5054 of 5 stars	0.0	3.0	0.0	0.0	2.2	1.7	0.0
SXTC China SXT Pharmaceuticals	0.9274 of 5 stars	0.0	5.0	0.0	0.0	2.2	0.0	0.6
YMTX Yumanity Therapeutics	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALLK Allakos	2.25	Hold	$2.00	507.72% Upside
COEP Coeptis Therapeutics	0.00	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	0.00	N/A	N/A	N/A
YMTX Yumanity Therapeutics	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALLK Allakos	N/A	N/A	N/A	N/A	$1.93 per share	N/A
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	$1.61 per share	N/A
SXTC China SXT Pharmaceuticals	$1.82M	106.24	N/A	N/A	$243.66 per share	0.01
YMTX Yumanity Therapeutics	$4.84M	0.00	N/A	N/A	$2.28 per share	0.00

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALLK Allakos	-$185.70M	-$1.32	N/A	N/A	N/A	N/A	-140.87%	-86.22%	8/6/2025 (Estimated)
COEP Coeptis Therapeutics	-$10.88M	-$5.80	N/A	∞	N/A	N/A	-282.39%	-127.23%	N/A
SXTC China SXT Pharmaceuticals	-$3.10M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
YMTX Yumanity Therapeutics	-$39.50M	-$3.00	N/A	N/A	N/A	-660.61%	-263.34%	-107.08%	N/A

Latest YMTX, ALLK, COEP, and SXTC Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/6/2025	Q2 2025	ALLK Allakos	-$0.24	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	COEP Coeptis Therapeutics	N/A	-$1.11	N/A	-$1.11	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALLK Allakos	N/A	N/A	N/A	N/A	N/A
COEP Coeptis Therapeutics	N/A	N/A	N/A	N/A	N/A
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
YMTX Yumanity Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALLK Allakos	N/A	6.08	6.08
COEP Coeptis Therapeutics	0.02	0.82	0.82
SXTC China SXT Pharmaceuticals	N/A	N/A	N/A
YMTX Yumanity Therapeutics	N/A	2.21	2.21

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALLK Allakos	84.64%
COEP Coeptis Therapeutics	13.88%
SXTC China SXT Pharmaceuticals	5.02%
YMTX Yumanity Therapeutics	25.10%

Insider Ownership

Company	Insider Ownership
ALLK Allakos	16.12%
COEP Coeptis Therapeutics	24.25%
SXTC China SXT Pharmaceuticals	3.95%
YMTX Yumanity Therapeutics	12.45%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALLK Allakos	190	90.38 million	74.94 million	Optionable
COEP Coeptis Therapeutics	2	3.51 million	2.66 million	Not Optionable
SXTC China SXT Pharmaceuticals	90	116.03 million	111.45 million	Not Optionable
YMTX Yumanity Therapeutics	40	10.86 million	9.50 million	Not Optionable

YMTX, ALLK, COEP, and SXTC Headlines

Recent News About These Companies

Board of Governors

July 20, 2024 | bc.eduB

JSPR Jasper Therapeutics, Inc.

March 20, 2024 | seekingalpha.com

Cara Therapeutics Inc CARA

November 3, 2023 | morningstar.comM

Yumanity Therapeutics Inc.

October 6, 2023 | thestreet.com

Former Onyx CEO Returns to Biotech to Launch Boston Start Up

July 5, 2023 | thestreet.com

Kineta raises $6M through registered direct offering

May 1, 2023 | bizjournals.com

Colorectal Cancer Therapeutics Market Size to Surpass US$ 24.58 Billion by 2030 - Growth Plus Reports

February 22, 2023 | finance.yahoo.com

Yumanity Therapeutics's Return On Capital Employed Insights

December 26, 2022 | msn.com

Kineta finalizes reverse merger with Yumanity, secures additional funding

December 20, 2022 | bizjournals.com

Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to ...

December 5, 2022 | bakersfield.comB

Yumanity Therapeutics Declares Special Dividend In Connection with Proposed Asset Sale to Janssen and Merger with Kineta

December 5, 2022 | finance.yahoo.com

Why Is Yumanity Therapeutics (YMTX) Stock Up Today?

December 5, 2022 | investorplace.com

Yumanity Therapeutics Inc: Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

November 14, 2022 | finanznachrichten.de

Yumanity Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Developments

November 14, 2022 | finance.yahoo.com

Yumanity Therapeutics Announces Effectiveness of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta, Inc.

November 10, 2022 | finance.yahoo.com

Yumanity Therapeutics Announces Filing of Registration Statement on Form S-4 In Connection With Proposed Asset Sale to Janssen and Merger with Kineta

August 29, 2022 | finance.yahoo.com

Yumanity Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Developments

August 4, 2022 | finance.yahoo.com

Glioblastoma Pipeline Analysis: Key Pharma Players Set to Develop Novel Therapies and Explore Countless Opportunities

July 14, 2022 | medgadget.com

YUMANITY THERAPEUTICS INVESTOR ALERT by the Former Attorney General of…

July 5, 2022 | lawyer-monthly.comL

Inside Kineta's plans after unveiling reverse merger deal

June 8, 2022 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

YMTX, ALLK, COEP, and SXTC Company Descriptions

Allakos NASDAQ:ALLK

Allakos Inc., a clinical stage biotechnology company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases in the United States. The company's lead product candidate is AK006, which in a Phase I clinical trial for the treatment of chronic spontaneous urticaria (CSU) and other indications. The company was incorporated in 2012 and is headquartered in San Carlos, California.

Coeptis Therapeutics NASDAQ:COEP

$9.77 -0.07 (-0.71%)

Closing price 04:00 PM Eastern

Extended Trading

$9.73 -0.04 (-0.42%)

As of 07:38 PM Eastern

Coeptis Therapeutics Holdings, Inc., a biopharmaceutical company, develops cell therapy platforms for patients with cancer. Its product portfolio consists of CD38-GEAR-NK, a cell therapy for the treatment of CD38-related cancers, including multiple myeloma, chronic lymphocytic leukemia, and acute myeloid leukemia; SNAP-CAR, a CAR T cell therapy platform co-administered with tagged, tumor-specific antibodies to potentially target different tumor types, including hematological malignancies and solid tumors; and CD38-Diagnostic, an in vitro screening tool to analyze if cancer patients might be appropriate candidates for anti-CD38 mAb therapy. The company also offers its drugs for acute myeloid leukemia and acute respiratory diseases. Coeptis Therapeutics Holdings, Inc. has co-development agreement Vici Health Sciences, LLC to co-develop and share ownership rights to CPT60621 for the treatment of Parkinson's Disease. The company was founded in 2017 and is headquartered in Wexford, Pennsylvania.

China SXT Pharmaceuticals NASDAQ:SXTC

$1.66 0.00 (-0.18%)

Closing price 03:58 PM Eastern

Extended Trading

$1.65 -0.02 (-0.90%)

As of 06:47 PM Eastern

China SXT Pharmaceuticals, Inc., a pharmaceutical company, engages in the research, development, manufacture, marketing, and sale of traditional Chinese medicine pieces (TCMP) in China. The company offers advanced, fine, and regular TCMP products, and raw medicinal material, such as ChenXiang, SanQiFen, HongQi, SuMu, JiangXiang, CuYanHuSuo, XiaTianWu, LuXueJing, XueJie, ChaoSuanZaoRen, HongQuMi, ChuanBeiMu, HuangShuKuiHua, WuWeiZi, DingXiang, RenShen, QingGuo, JueMingZi, and ShaRen. It provides its products under the Suxuantang, Hui Chun Tang, and Tong Ren Tang brands. The company had an end-customer base of pharmaceutical companies, chain pharmacies, and hospitals in 10 provinces and municipalities in China. China SXT Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Taizhou, China.

Yumanity Therapeutics NASDAQ:YMTX

Yumanity Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of treatments for neurodegenerative diseases caused by protein misfolding. The company focuses on discovering disease-modifying therapies to treat neurodegenerative diseases, including Parkinson's disease, dementia with Lewy bodies, multiple system atrophy, amyotrophic lateral sclerosis, and frontotemporal lobar degeneration. Its lead program is YTX-7739, a novel small molecule that is in Phase I clinical trial for the treatment of Parkinson's disease and related disorders of a-synuclein. The company is also developing YTX-9184, which is in preclinical studies to treat neurological disorders. Yumanity Therapeutics Inc. has a license and research collaboration agreement with Merck Sharp & Dohme Corp. The company was founded in 2014 and is headquartered in Boston, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time